April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

Perspectum raises $36M for digital diagnostics
Perspectum Diagnostics Ltd. raised $36 million in an undisclosed round co-led by Blue Venture Fund and HealthQuest Capital, with participation from Oxford Science Innovation, Puhua Capital, the University of Oxford and other existing investors. Perspectum will use the funding to commercialize its LiverMultiScan platform, expand its imaging-based CRO services and develop digital technologies for biliary disease, diabetes and cancer. LiverMultiScan platform is approved in U.S. and Europe for diagnosis of chronic liver disease by extracting data from MRI scans.

Akeso sets Hong Kong IPO terms
Antibody company Akeso Inc. proposed to sell 159.5 million shares at HK$14.88-HK$16.18 in an IPO on the Hong Kong stock exchange. At the midpoint, Akeso would raise HK$2.5 billion (US$319.5 million) and be valued at HK$11.9 billion. Akeso plans to submit its first NDA for lead anti-PD-1 antibody penpulimab (AK105) to treat classical Hodgkin lymphoma in mid-2020...